ViroClinics Biosciences B.V., Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands.
Vaccine. 2011 Nov 15;29(49):9265-70. doi: 10.1016/j.vaccine.2011.09.049. Epub 2011 Sep 22.
The advent of the H1N1 influenza pandemic (pH1N1) in 2009 triggered the rapid production of pandemic influenza vaccines, since seasonal influenza vaccines were expected and demonstrated not to provide significant cross-protection against the newly emerged pandemic virus. To increase vaccine production capacity and further evaluate the effectiveness of different candidate pandemic influenza vaccines, the World Health Organization stimulated the evaluation of different vaccination concepts including the use of live attenuated influenza vaccines (LAIVs). Therefore, we have immunized ferrets intranasally with a single dose of pH1N1-LAIV from different manufacturers. They all induced adequate serum HI antibody titers in the ferrets and protected them against intratracheal wild-type pH1N1 virus challenge: pH1N1 virus replication in the upper respiratory tract and lungs was reduced and no disease signs or severe broncho-interstitial pneumonia were observed in any of the vaccinated ferrets. These data together with the relatively efficient production process emphasize the potential of the LAIV concept for pandemic preparedness.
2009 年甲型 H1N1 流感大流行（pH1N1）的出现促使人们迅速生产大流行流感疫苗，因为人们预计并证明季节性流感疫苗不能对新出现的大流行病毒提供显著的交叉保护作用。为了提高疫苗生产能力，并进一步评估不同候选大流行流感疫苗的有效性，世界卫生组织鼓励评估不同的疫苗接种概念，包括使用减毒活流感疫苗（LAIV）。因此，我们通过鼻腔内接种途径给雪貂接种了来自不同制造商的单剂量 pH1N1-LAIV。这些疫苗都在雪貂体内诱导了足够的血清 HI 抗体滴度，并保护它们免受气管内野生型 pH1N1 病毒攻击：pH1N1 病毒在上呼吸道和肺部的复制减少，在任何接种的雪貂中都没有观察到疾病迹象或严重的细支气管炎-间质性肺炎。这些数据以及相对高效的生产工艺强调了 LAIV 概念在大流行准备中的潜力。
